Market Overview
The Latin America insulin delivery devices market covers disposable syringes, reusable and prefilled insulin pens, insulin pumps, and increasingly smart connected pens and attachments used in diabetes management. The market is valued at roughly USD 2.73 billion in 2025 and is projected to grow at about 6.9% annually, placing the region in a medium-growth tier relative to global peers. Demand is anchored in the region's expanding diabetic population, particularly in Brazil and Mexico, where type 2 diabetes prevalence continues to climb alongside urbanization and aging demographics.
- •2025 market value: approximately USD 2.73 billion
- •Forecast CAGR of around 6.9% through the late 2020s
- •Brazil, Mexico, Argentina, Colombia, and Chile represent the principal national markets
Growth Drivers
Rising diabetes incidence is the foundational demand driver, with Latin America experiencing one of the fastest-growing diabetic populations globally. Expanding public and private health coverage, including broader reimbursement for insulin pens and pumps in countries such as Brazil and Mexico, is improving device accessibility. The introduction of smart connected pens, integration with continuous glucose monitoring, and pharmacist-supported digital diabetes programs are further accelerating adoption among both type 1 and insulin-requiring type 2 patients.
- •Rising type 1 and type 2 diabetes prevalence across major Latin American economies
- •Gradual inclusion of pens, pumps, and CGM-compatible devices in public formularies
- •Digital health initiatives and pharmacist-led diabetes care programs in Brazil and Mexico
Segmentation and Regional Analysis
By product type, the market is segmented into insulin syringes, insulin pens (reusable and prefilled), insulin pumps, and emerging smart connected devices, with pens currently representing the largest share and pumps expanding fastest in urban tertiary-care centers. Brazil leads regional revenue, followed by Mexico and Argentina, while Colombia, Chile, and Peru are emerging growth pockets as private insurance coverage broadens. Distribution channels span hospital pharmacies, retail pharmacies, and online platforms, with retail pharmacies dominating volume sales.
- •Pens hold the largest product share; pumps are the fastest-growing segment
- •Brazil and Mexico together account for the majority of regional revenue
- •Retail pharmacy chains lead distribution, with e-commerce growing steadily
Trends and Outlook
What are the recent trends and outlook?
The clearest trajectory is toward digitally enabled insulin delivery, with smart pens, Bluetooth-connected pen caps, and pump-CGM hybrid systems moving from premium to mainstream offerings. WHO-aligned affordability initiatives and Brazilian, Mexican, and Argentine public health programs are expected to expand access to advanced devices among pediatric and young adult type 1 diabetes populations, where uptake disparities remain pronounced. Over the medium term, the market outlook points to sustained mid-single-digit growth, with smart and automated delivery formats capturing an increasing share of incremental revenue.
- •Smart connected pens and CGM-integrated pumps are the primary innovation frontier
- •Affordability and equity programs are expected to close access gaps in pediatric type 1 diabetes
- •Mid-single-digit growth is forecast to continue, led by pen and smart device categories
Get in touch and our analysts will be happy to help with custom market sizing, deeper segmentation, supplier detail or a bespoke study built for you.
Connect to an analyst →Market size and forecast are Claight Analysis, informed by public research and industry data. Historical years before 2025 and all forecast years are Claight estimates at the stated CAGR. Retrieved 2026.